12th Congress of the European Hematology ... - Haematologica

12 th Congress of the European Hematology Association
residual) disease during treatment. Moreover, in AML and CML, measurement
of tryptase is of prognostic significance. All in all, tryptase is recommended
as a new important serum-marker in clinical hematology.
1113
RELATIONSHIP OF SERUM FREE LIGHT CHAIN LEVELS AND SELECTED BIOLOGICAL
PARAMETERS IN PATIENTS WITH MULTIPLE MYELOMA
T. Pika, 1 J. Minarik, 2 M. Zemanova, 2 M. Budikova, 3 J. Bacovsky, 2
V. Scudla2 1 Olomouc University Hospital, OLOMOUC; 2 3rd Department of Internal Medicine,
OLOMOUC; 3 Department of Nuclear Medicine, OLOMOUC, Czech
Republic
Backround. The presented study is focused upon the evaluation of relation
of serum free light chain levels (FLC) kappa, lambda and their ratio
(K/L ratio) and levels of selected biological parameters in group of
patients with multiple myeloma assesed at the time of diagnosis. Methods.
Prospective study included 102 patients with multiple myeloma,
examined during two year period. Serum FLC levels were assesed using
Freelite Immunotech system, for the evaluation of serum levels of
analysed parameters were used following methods: radioenzymatic
assay (thymidinekinase), radioimmunoanalysis (β-2-microglobulin,
ICTP, PINP), enzymoimmunoassay (sIL-6R, sVCAM, sICAM-1, sOPG)
and quantitative enzymatic immunoassay (sHGF, sVEGF, syndecan-
1/CD138 and sFas). Spearmanãs test was used for statistical evaluation.
Kappa and lambda secretion were evaluated separately. Results. In kappa
group was found a significant correlation between serum levels of
dominant chain kappa and serum values of ‚-2- microglobulin (r=0,344,
p=0,005), thymidinekinase (r=0,263, p=0,035), ICTP (r=0,402, p=0,001),
PINP (r=0,264, p=0,039), sOPG (r=0,328, p=0,028), syndecan-1/CD138
(r=0,255, p=0,046) and sFas (r=0,418, p=0,001). Also significant correlation
between K/L ratio and levels of ‚-2-microglobulin (r=0,316, p=0,01),
thymidinekinase (r=0,274, p=0,027), ICTP (r=0,346, p=0,006), PINP
(r=0,261, p=0,042), syndecan-1/CD138 (r=0,283, p=0,026) and sFas (r=
0,377, p=0,002) was found. In lambda group correlation analysis revealed
a mutual relationship between serum levels of dominant chain lambda
and ‚-2-microglobulin (r= 0,476, p=0,003), ICTP (r=0,375, p=0,022),
sVCAM (r= 0,383, p=0,019), sHGF (r=0,441, p=0,006) and sFas (r=0,334,
p=0,040). Correlation of K/L index was found to ‚-2-microglobulin (r=-
0,473, p=0,003), thymidinekinase (r=-0,412, p=0,011), ICTP (r=-0,331,
p=0,045), PINP (r=-0,409, p=0,012), sHGF (r=-0,357, p=0,028), syndecan-1/CD138
(r=-0,449, p=0,005) and sFas (r=- 0,371, p=0,022). There
was found no relation between alternative light chains and analysed
parameters in both groups. Conclusions. The above study showed a correlation
of serum free light chain levels and serum values of some selected
biological parameters, especially ‚-2-microglobulin, thymidinekinase,
ICTP, PINP, syndecan-1/CD138 and sFas at the time of diagnosis. It confirms
close relation between bone marrow microenviroment, biological
properties of clonal plasma cells and intensity of free light chain production.
K/L index seems to be more sensitive, than only kappa or lambda
chain serum levels.
Founded by VVZ-HOK (6198959205).
1114
ISOFLAVONES: EFFECTS ON THE COAGULATION AND FIBRINOLYTIC SYSTEM AND LIPID
PROFILE IN POSTMENOPAUSAL WOMEN
D. Romana Alves Rios, 1 M. Torqueti Toloi, 2 M. Boneti Agostinho
Montes, 1 S. Antonio Franceschini, 1 E. Talarico Rodrigues, 1 A. Cardoso1 1 University of Sao Paulo, RIBEIRAO PRETO, Brazil; 2 Faculty of Pharmaceutical
Sciences of Ri, RIBEIRAO PRETO, Brazil
Background. The incidence of cardiovascular disease (CVD) is associated
with unfavorable alterations of the lipid profile and haemostasis,
proceeding from decrease of the estrogenic activity in postmenopausal
women. Hormonal Replacement Therapy (HRT) has been much debated
because some studies show HRT increases breast cancer predisposition
and it does not protect against cardiac diseases. Attempting to reach
treatment to menopause symptoms, minimizing side effects, we suggest
isoflavone, a natural compound extracted from soy (Glycine max) protein
that has a effect estrogen like. Aims. To evaluate the effects of the
isoflavone on haemostasis and lipids levels in healthy postmenopausal
women. Methods. In this double blind placebo-controlled study, 47 postmenopausal
women of age 47-66 years received 40mg Isoflavone-GALE-
NA? (n=25) or 40mg casein placebo (n=22). Levels of hemostatic factors
PT, APTT, activity factors VII and X, and fibrinogen, TAT, F1+2,
410 | haematologica/the hematology journal | 2007; 92(s1)
antithrombin, protein C, total and free protein S, plasminogen, PAI-1 and
D-dimers and lipids [total cholesterol/TC, triglycerides/TG, High Density
Lipoprotein/HDL, Low Density Lipoprotein/LDL and Very Low
Density Lipoprotein/VLDL] were measured at baseline and 6 months.
The therapy were examined for FSH e ‚-estradiol levels. Urinary
isoflavone concentrations (genistein and daidzein) were measured as
marker of both compliance and absorption using high performance liquid
chromatography. Results. Levels of hemostatic variables did not
change significantly throughout the study in isoflavone group; however
isoflavone group experienced statistically significant reduction in plasma
concentration of F1+2 (11,5%); both groups experienced statistically
significant reduction in antithrombin, protein C and free protein S levels.
Significant increase in D-dimers were observed only in the isoflavone
group. PAI-1 levels increased significantly in the placebo group. Levels
of lipids (LDL and TC) decreased no significant similarly in both groups.
HDL decreased significantly in the isoflavone group (8,1%), but the
change was not different to the placebo group (13,81%). Furthermore,
in both groups were increased no significant of levels VLDL and TG.
Conclusions. The results of the current study do not support biologically
significant estrogenic effects of isoflavone on parameters assessed, however
further research will be necessary to definitively asses the safety and
efficacy of isoflavone.
1115
LIFE EXPECTANCY IN TYPE 1 (NON-NEURONOPATHIC) GAUCHER DISEASE
S. vom Dahl, 1 P.B. Deegan, 2 K. Kacena, 3 P.K. Mistry, 4 G.M. Pastores, 5
N. Weinreb6 1 St. Franziskus-Hospital, COLOGNE, Germany; 2 Addenbrooke’s Hospital,
CAMBRIDGE, United Kingdom; 3 Genzyme Corp., CAMBRIDGE, USA;
4 Yale University School of Medicine, NEW HAVEN, USA; 5 New York School
of Medicine, NEW YORK, USA; 6 University Research Medical Center, CORAL
SPRINGS, USA
Aims. Analyses were conducted to estimate life expectancy at birth of
patients with type 1 (non-neuronopathic) Gaucher disease (GD), the
most frequent lysosomal storage disease. Methods. The GD population
included all patients with type 1 GD registered in the International Collaborative
Gaucher Group (ICGG) Gaucher Registry. Life expectancy
was calculated according to the standard life table method (Palmore and
Gardner, 1996), and compared with the United States as a reference
population (World Population Prospects, 2002, UN). Approximately
40% of GD patients came from the U.S. The life expectancy of the reference
population was similar to that for developed nations (as defined
by the UN). The gender distribution in GD was similar to that of the general
population. Results. The type 1 Gaucher population of 2,876 patients
had 99 reported deaths in 13,499 person-years of follow-up. The average
life expectancy of the type 1 GD population was 69.7 years, and the
life expectancy of the reference population was 77.1 years. Analyses
restricted to the US population of patients with type 1 GD yielded a life
expectancy of 71.5 years, based on 65 deaths in 6,400 person-years.
Summary and Conclusions. The ICGG Gaucher Registry represents the
single largest dataset on GD patients worldwide. The current life
expectancy at birth of people with type 1 GD is about 7.4 years less than
the reference population. Additional analyses on causes of death and the
influence of factors such as enzyme replacement therapy with
imiglucerase and therapeutic splenectomy on life expectancy are
planned.
Reference
Palmore JA, Gardner GW. Measuring Mortality, Fertility and Natural Increase.
A self-teaching guide to elementary measures. Honolulu, Hawaii: East-
West Center Publisher, 1996, pages 35-61.
1116
IMATINIB PLUS CHEMOTHERAPY IN ADULT PATIENTS WITH PHILADELPHIA
CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH + ALL):
AN EXPLORATORY COST-EFFECTIVENESS ANALYSIS FOR THE UNITED KINGDOM
J. Stephens, K.T. Carpiuc, M.F. Botteman
Pharmerit North America LLC, BETHESDA, USA
Background. Patients diagnosed with Ph + ALL have few effective treatment
options and poor prognosis. Imatinib combined with conventional
chemotherapy (CC) in Ph + ALL patients has produced encouraging